By addressing considerations of efficacy and safety of drugs and chemicals used to combat COVID-19, virtually in real-time, this book documents and highlights the advances in science and place the toxicology, pharmaceutical science, public health and medical community in a better position to advise in future epidemics.
This first volume chronicles the early stages of the outbreak and world-wide spread of SARS-Cov-2 (COVID-19) and delineates the role of several disciplines in therapeutic and control measures. Documenting the epidemiologic response from China, the clinical evaluation, pathology and intial therapeutics that were available during the first 6 months and onwards of the outbreak, this book records how the response to the pandemic was mounted and how various branches of science and research combined to rapidly expand our understanding of the disease.
What We Know About the Life-threatening Novel Human Coronavirus;
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Structure,
Lifecycle, and Replication Machinery;
Accumulated Epidemiological Lessons and China's COVID-19 Response;
Clinical Presentation, Pathophysiology and Histopathology;
Evaluation of the Disease, Sample Collection and Diagnostics;
Therapeutic Options Initially Available for COVID-19 Patients and Initial
Clinical Trials;
Clinical Epidemiology of Coronavirus Disease 2019: Infectivity, Clinical
Spectrum and Presentation, and Population Distribution;
SARS-CoV-2 Genomics and Host Cellular Susceptibility Factors of COVID-19;
Infection and Pathogenesis of SARS-CoV-2:an Immunological Perspective;
Neurological Manifestations in COVID-19;
COVID-19 and Coagulopathy;
COVID-19 Endocrinopathies: Implications for Care;
Potential Risks of COVID-19 in Reproductive Health;
Clinical Autopsy in COVID-19;
COVID-19 Pharmacotherapy Present and Future;
Knowledge from Human Relevant Cell, Tissue and Mathematics-based Methods as
Key Tools for Understanding COVID-19 Dynamics, Kinetics, Symptoms, Risk
Factors and Non-conventional Treatments;
Michael D. Waters, holds a Ph.D. in Biochemistry from the University of North Carolina School of Medicine at Chapel Hill and a B.S. in Pre-medicine (Chemistry and Biology) from Davidson College. He is a former government scientist with more than 35 years of experience in research and research management positions at EPA and NIH/NIEHS and six years of private sector experience as Chief Scientific Officer at Integrated Laboratory Systems, Inc. His research interests have centered on the evaluation of chemically-induced mutations and altered molecular expression in the etiology of genetic disease. He is a widely-published scientist having published well over 100 peer-reviewed in authoritative international scientific journals. He has edited Mutation Research-Reviews for nearly 20 years and has held adjunct professorships at both the University of North Carolina and at Duke University for many years. He served as President of both the Environmental Mutagen Society and the International Association of Environmental Mutagen Societies (now the Environmental Mutagenesis and Genomics Society and the International Association of Environmental Mutagenesis and Genomics Societies, with more than seven thousand members worldwide). The databases he has developed and a number of his publications are recognized as important advances that have significantly impacted the fields of genetic toxicology, carcinogenesis, toxicogenomics, and risk assessment.
Lisainfo e-raamatute kohta